Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Survey or statistical program
Results
All (3)
All (3) ((3 results))
- Articles and reports: 88F0006X2003013Description:
This paper used data from the 2001 Biotechnology Use and Development Survey (BUDS) to look into bioproduct development using biotechnologies. Results show that the development of bioproducts has become an intrinsic part of the activities of Canadian biotechnology firms.
Release date: 2003-12-08 - 2. A discussion of the emerging nanotechnology ArchivedArticles and reports: 88-003-X20030026561Geography: CanadaDescription:
Nanotechnology is an emerging technology. Has it reached the point that warrants the development of a comprehensive statistical measurement program? If so, what indicators should be used? Major spending initiatives in nanotechnology investing are currently underway. There is precedence for using developed methods and techniques to address the questions 'who,' 'what,' 'where' and 'why.' Statistics Canada's experience may be invaluable in the development of a nanotechnology statistical program.
Release date: 2003-06-27 - Articles and reports: 88-003-X20030026570Geography: CanadaDescription:
In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?
Release date: 2003-06-27
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (3)
Analysis (3) ((3 results))
- Articles and reports: 88F0006X2003013Description:
This paper used data from the 2001 Biotechnology Use and Development Survey (BUDS) to look into bioproduct development using biotechnologies. Results show that the development of bioproducts has become an intrinsic part of the activities of Canadian biotechnology firms.
Release date: 2003-12-08 - 2. A discussion of the emerging nanotechnology ArchivedArticles and reports: 88-003-X20030026561Geography: CanadaDescription:
Nanotechnology is an emerging technology. Has it reached the point that warrants the development of a comprehensive statistical measurement program? If so, what indicators should be used? Major spending initiatives in nanotechnology investing are currently underway. There is precedence for using developed methods and techniques to address the questions 'who,' 'what,' 'where' and 'why.' Statistics Canada's experience may be invaluable in the development of a nanotechnology statistical program.
Release date: 2003-06-27 - Articles and reports: 88-003-X20030026570Geography: CanadaDescription:
In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?
Release date: 2003-06-27
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: